NAPRT and ovarian carcinoma: In xenograft models of ovarian carcinoma, silencing NAPRT or inhibiting the enzyme with 2-hydroxinicotinic acid resulted in sensitization to FK866; similarly, overexpression of NAPRT induced resistance in these models, supporting the idea that NAPRT amplification and overexpression represent a mechanism of resistance to NAMPT inhibitors[39].